DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20202178

A prospective study of adverse drug reactions associated with chemotherapy in patients of carcinoma head and neck in Government Cancer Hospital Indore, India

Sameer Pandit, Manish Verma, Pooja Solanki Mishra

Abstract


Background: Adverse drug reactions (ADRs) has become one of the major health issues due to wide use of medications worldwide. Chemotherapy is one of the treatment lines in which multiple drugs are commonly used for long term in cancer patients, are more prone to cause ADR.

Methods: Head and neck cancer patients admitted in government cancer hospital, Indore for chemotherapy were included in study for a period of 6 month from March to August 2019. Data from chemotherapy related ADR was obtained either from patient’s case reports or interview of patients, recorded in suspected adverse drug reaction reporting form (version 1.3) of CDSCO and analyzed.

Results: During 6 months duration total 126 patients (M:F=108:18) were enrolled in the study, among which 251 ADRs were reported. Majority of ADRs occur in 45-60 years of age group followed by 30-45 years. Paclitaxel, cisplatin, 5-florouracil (5-FU) combinations (45.2%) implicated highest number of ADRs followed by paclitaxel and carboplatin combination (38%). Most common ADR was alopecia and constipation. ADR related mostly with GIT system followed by integumentary, haematological system while CNS was least affected.

Conclusions: In this study Ca tongue was most commonly seen head and neck cancer followed by Ca buccal mucosa. Age group 45-60 years were commonly affected. Paclitaxel, cisplatin, 5-FU combination was commonly used regimen and primary cause of ADR. Alopecia and constipation were noted to be most common ADR. Other ADRs reported were mild and easily manageable.


Keywords


Adverse drug reactions, Chemotherapy, Head and neck cancer

Full Text:

PDF

References


Chabner BA, Amrein PC, Druker BJ. Bruntan LL, Lazo JS, Parker KL. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. USA: MaGraw-Hill Companies, Inc; 2006. Antineoplastic agents. 2006;37(1):42-6.

Muller T. Typical medication errors in oncology: Analysis and prevention strategies. Onkologie. 2003;26:539-44.

WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines. Available at: http://www. whqlibdoc.who.int/hq/2004/WHO_EDM_2004.8.pdf. Accessed on 15 December 2009.

Glossary of Terms Used in Pharmacovigilance; January. 2013. Available at: http://www.whoumc. org/DynPage.aspx?id=97224&mn1=7347&mn2=7252&mn3=7257. Accessed on 30 July 2013.

De A. Monitoring of suspected adverse drug reactions in oncology unit of an urban multi-speciality teaching hospital. Int J Res Pharm Biomed Sci. 2010;1:1-32.

Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S, et al. Adverse drug reactions in Germany: Direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626-34.

Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006;54:226-33.

Brown SD, Landry FJ. Recognizing, reporting, and reducing adverse drug reactions. South Med J. 2001;94:370-3.

Safety of Medicines. Available at: http://www.whqlibdoc.who.int/hq/2002/.WHO_EDM_QSM_2002.2.pdf. Accessed on 2nd January 2015.

Surendiren A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: an evaluative study. Indian J Pharmacol. 2010;42(1):40-3.